835 results on '"Park, Sophie"'
Search Results
152. Pitfalls and pleasures of pick-and-mix careers: portfolio working and whole-person medicine in general practice
153. Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation
154. Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network
155. De novo adult acute myeloid leukemia patients’ display at diagnosis functional deregulation of redox balance correlated with molecular subtypes and overall survival
156. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
157. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD
158. Hypokalaemia tetraparesis and rhabdomyolysis: aetiology discovered on a normal lung radiograph
159. Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients
160. Dyserythropoiesis Evaluated By Red Score and Hepcidin/Ferritin Levels Predicts Response to Epoetin Zeta in Lower Risk MDS
161. Reorganisation of general practice: be careful what you wish for
162. Comparaison des quantités de vésicules extracellulaires des concentrés de globules rouges (CGR) au cours du stockage et selon le procédé de préparation à partir de sang total
163. Effets des vésicules extracellulaires issues des CGR sur l’hématopoïèse des syndromes myélodysplasiques
164. Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate
165. Alma-Ata 40th birthday celebrations and the Astana Declaration on Primary Health Care 2018
166. Facilitators and barriers to teaching undergraduate medical students in general practice
167. Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study
168. Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival
169. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
170. Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
171. The gift in A&E: re-framing the medical case presentation through Mauss
172. Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
173. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial
174. Understanding the impact of delegated home visiting services accessed via general practice by community-dwelling patients: a realist review protocol
175. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
176. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification
177. Lost in reviews: Looking for the involvement of stakeholders, patients, public and other non‐researcher contributors in realist reviews.
178. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis
179. Faire vivre et grandir une communauté de chefs de service : Acte 2 en hématologie
180. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
181. Educational potential of using virtual patients for promoting interprofessional learning between medical and pharmacy students: A qualitative study
182. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies
183. Evidence synthesis software
184. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
185. Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes
186. Do primary care placements influence career choice: What is the evidence?
187. Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes
188. Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)
189. Exploring provision of Innovative Community Education Placements (ICEPs) for junior doctors in training: a qualitative study
190. Which second line treatments after ESA failure?
191. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
192. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
193. Patient participation in general practice based undergraduate teaching: a focus group study of patient perspectives
194. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
195. Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes
196. Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment
197. Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry
198. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases
199. Caring for quality of care: symbolic violence and the bureaucracies of audit
200. Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.